Episode Details

In the early days of the COVID-19 pandemic when there were no vaccines or treatments, convalescent plasma—antibody-containing blood from people who recovered from COVID—saved countless lives through Emergency Use Authorization. In this episode: special guest host Thomas Locke of MMI Monthly: From Bench To Breakthrough discusses the evolution of CCP therapy, from emergency use during the pandemic to now, nearly five years later, crossing the finish line with recent FDA approval as a potential treatment for immunocompromised patients.

David Sullivan is a professor in Molecular Microbiology and Immunology and a researcher at the Johns Hopkins Malaria Research Institute.

Thomas Locke is the host of MMI Monthly: From Bench to Breakthrough and Malaria Minute,  podcasts from the department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health.

• Bloomberg School Researchers Support First Blood Center to Receive Full FDA Approval to Provide Convalescent Plasma for Patients Who Are Immunocompromised—Johns Hopkins Bloomberg School of Public Health

• Convalescent Plasma Offers ‘Blueprint’ For Future Pandemics—The Hub

• How a Boy’s Blood Stopped an Outbreak—The Wall Street Journal (Opinion)